Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Mannkind Corporation
A Phase 3, open label, multicenter, safety follow up trial to convert the treatment of subjects currently using Exubera to treatment with TI Inhalation Powder
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subject has type 1 or type 2 diabetes mellitus and is currently being treated with or has been treated with Exubera.
Subject has a severe phobia to sc injections of insulin (needle phobia) preventing conventional treatment OR has impaired sc insulin absorption
You may not be if
Smoking in the previous 6 months
History of asthma or chronic obstructive pulmonary disease (COPD) or any other significant pulmonary disease, or exposure to pulmonary toxins.
Clinically significant pulmonary abnormalities on chest high-resolution computed tomography (HRCT).
PFT results prior to transferring to TI Inhalation Powder showing any of the following: FEV1 \< 70% of predicted, FVC \< 70% of predicted, DLCO \< 70% of predicted, TLC \< 80% of predicted.
Allergy to insulin
Clareo Health | Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
